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INTRODUCTION 
Stroke is a global health problem. It is the second most common cause of death 
and fourth leading cause of disability worldwide
[1]
. Around 20 million people each year 
will suffer from stroke and about 5 million people among them will not survive 
[2,3]
. In 
developed countries, stroke is the first leading cause for disability, second leading cause 
of dementia and third leading cause of death. Stroke is also a predisposing factor for 
epilepsy, falls and depression in developed countries 
[4]
 and is a leading cause of 
functional impairments, with 20% of survivors requiring institutional care after 3 months 
and 15% - 30% being permanently disabled
[5]
. 
The World  Health  Organization (WHO)  definition  of  stroke  is: “rapidly  
developing  clinical  signs  of focal  (or  global)  disturbance  of  cerebral  function, with  
symptoms  lasting  24 hours  or  longer  or  leading  to  death, with  no  apparent  cause  
other  than  of  vascular  origin.” 
Morbidity and Mortality associated with Stroke  
Global Stroke estimates  
• 400-800 strokes per 100,000 [6] 
• 5.7 million Deaths [7]  
• 16 million new acute strokes every year[1] 
• 28,500,000 DALYs (disability adjusted life-year)[8] 
• 28-30 day case fatality ranges from 17%-35% Stroke[9] 
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Morbidity and Mortality in India   
• Prevalence 90-222 per 100,000 [2] 
• 102, 620 million deaths [10] 
• 1.44-1.64 million cases of new acute strokes per year[11,12]  
• 6,398,000 DALYs[13] 
• 12% of strokes occur in the population aged <40 years [14] 
• 28-30 day case fatality ranges from 18-41% [2,3] 
  The most common cause of ischemic stroke in India is large vessel atherosclerosis. 
Common risk factors includehypertension, diabetes, smoking, alcohol  anddyslipidemia. 
These risk factors are not properly controlled due to poor public awareness and 
inadequate infrastructure. Number of people who benefit from thrombolytic therapy is 
very small. Various trials are being conducted for stemcell therapy in ischemic stroke. At 
present the best way to prevent stroke in the Indian scenario is to control the the risk 
factors of stroke. Interventional studies are also required which may give better outcome 
in the future. 
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FIGURE 1Crude prevalence rates for stroke Rural India 1970-2004 Urban India 
1973-2004 
 
      RURAL           URBAN 
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FIGURE 2: Stroke mortality rates across world 
 
It is a well known fact that if stroke patients have associated protein energy 
malnutrition they tend have poor outcome.
[25]
Recent studies have shown that serum 
albumin level is an independent predictor of ischemic stroke outcome
[26,27]
. Albumin as 
an independent predictor in ischemic stroke has not been studied significantly in Indian 
population. Therapeutic interventions like albumin infusion with tissue-plasminogen 
activator has been tried in murine models of acute ischemic stroke where positive results 
have been obtained. Albumin In Acute Stroke (ALIAS) trial was an interventional trial 
conducted in ischemic stroke patients which didn’t yield promising reports.If there is a 
suitable predictor of ischemic stroke outcome it will enable us to monitor and 
prognosticate.Later further studies may entail therapeutic interventions such as albumin 
infusion. 
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AIM 
To determine the prognostic value of Serum Albumin levels in Acute Ischemic 
Stroke by correlating its levels with clinical outcome. 
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MATERIALS AND METHODS 
STUDY DESIGN 
Hospital based prospective study 
SAMPLE SIZE: 50 
INCLUSION CRITERIA: 
All patients of age group more than 18 years with clinical and radiological 
evidence of acute ischemic stroke  
EXCLUSION CRITERIA: 
1) Cerebral hemorrhage of any etiology 
2) Liver disease (Alcohol intake >20 units/week for males,>14 units/week for 
females) 
3) Cardiac failure 
4) Nephrotic syndrome/diabetic nephropathy(urine albumin >2+) 
5) Protein losing enteropathies 
6) Malignancy 
7) Conditions mimicking stroke 
a) Metabolic                                          
-severe hyponatremia 
-hypoglycemia 
-hepatic encephalopathy    
-hyperglycemichyperosmolarnonketotic state             
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b) Psychiatric disorders         
-conversion disorder    
-malingering                        
-factitious disorder                                 
 
c) Infectious conditions 
-viral encephalitis 
-Bacterial meningitis 
-Brain abscess 
d) Cardiovascular 
- syncope 
- hypertensive encephalopathy 
e) Neurological conditions 
-seizure with Todd’s paralysis 
-brain tumor 
-demyelinating disorders 
-myasthenia gravis 
-Bell’s palsy 
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METHODOLOGY: 
The study is based on prospective collection of data in Ischemic stroke patients 
who fulfill the inclusion criteria stated above and who were admitted  in  medicine and 
neurology wards  in  a  tertiary  care  centre(PSGIMSR) where  systematic  computer  
coding  for  registry is  used.Diagnosis of ischemic stroke is based on clinical observation 
and radiological imaging. 
Blood samples for assessment of albumin was collected at admission within   36  
hours after stroke onset. Strokeseverity at presentation was determined by NIHSS score. 
Functional outcome was measured 1 week post admission and after 3 months during 
follow up using modified Rankin scale. 
Favourable score mRS:0-3 
 Unfavourable score mRS:4-6 
According  to  the  imaging  done  at baseline  and associated risk  factors,  the  
stroke  subtypes were classified  by using classification  developed  for  Trial  of  Org  
10172  in  Acute  Stroke  Treatment (TOAST). 
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TABLE 1 
TOAST  Classification  Of  Subtypes  Of  Acute  Ischemic  Stroke 
Large-artery atherosclerosis (embolus/thrombosis) 
Cardioembolism (high-risk/medium-risk) 
Small-vessel occlusion(lacunar) 
Stroke of other determined etiology 
 
Stroke of undetermined etiology 
a. Two or more causes identified 
b. Negative evaluation 
                     c. Incomplete evaluation 
 
Patients  are  examined  clinically in detail  and  their  severity was assessed  by  
National  Institute  of  Health  stroke  scale (NIHSS) at  baseline. 
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TABLE 2: National  Institute  of  Health  stroke  scale (NIHSS): 
STROKE STROKE  SEVERITY 
0 No  stroke  symptoms 
1-4 Minor  Stroke 
5-15 Moderate  Stroke 
16-20 Moderate  to  Severe  Stroke 
21-42 Severe  Stroke 
 
To  assess  the  clinical  outcome  of  the  patients,  mRS scoring  is  done  after 1 
week  and after  3  months  and  are  correlated  accordingly. mRS ranges from 0-6, and 
includes people with no disability to death. 
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TABLE 3: Modified Rankin Scale 
SCORE SYMPTOMS 
0 - No  symptoms 
1 - No significant disability. Able  to  carry  out  all  usual  activities, 
despite  some  symptoms 
2 - Slight disability. Able  to  look  after  own  affairs  without  
assistance, but  unable  to  carry  out  all  previous  activities 
3 - Moderate disability. Requires  some  help, but  able  to  walk  
unassisted 
4 - Moderately severe  disability. Unable  to  attend  to  own  bodily  
needs  without  assistance,  and  unable  to  walk  unassisted 
5 - Severe disability. Requires  constant  nursing  care  and  
attention, bedridden,  incontinent 
6 -Dead 
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Statistical tools: 
The data collected from the patients is tabulated using Microsoft Excel. The data 
has been reported in the tables as Percentages, Mean and Standard deviation. The data 
was analyzed using Chi-squaretest and ANOVA. Chi-square test has been used for 
categorical variables and ANOVA is applied forcomparison between groups. Statistical 
analysis for the data collected was done using SPSS(Statistical Package for Social 
Sciences) with the version of 16.0. The p value were tested at 5% levelof significance. 
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REVIEW OF LITERATURE 
History and Background: 
Stroke was first recognized by Hippocrates (460 to 370 BC), father of medicine some 
2400 years ago. Initially it was termed apoplexy in Greek (meaning “struck down by 
violence”). 
Johann Jacob Wepfer (1620–1695) was the next well renowned person in the field of 
stroke. He studied the corpses deceased due to apoplexy. He discovered that blood supply 
might be disrupted to the brain due to blocked arteries in a few or due to massive 
bleeding into the brain tissue
 [28]
. 
Rudolf Virchow, known as father of modern pathology, was the first to describe the 
mechanism of thromboembolism as a major factor causing stroke. In the mid nineteenth 
century , he described the term thrombosis which can detached to form an embolus 
causing cardio-embolic stroke
[29]
. 
Depending on the cause the term apoplexy was further categorised in the year 1928 and 
after which the term cerebrovascular accident came into play. In 2011, use of this term 
cerebrovascular accident was discouraged reasoning that the connotation of 
fortuitousness carried by the word accident insufficiently highlights the modifiability of 
the underlying risk factors
[30,31]
.  
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EPIDEMIOLOGY 
In India, the prevalence of stroke is increasing. The incidence of stroke increases 
exponentially from 30 years of age, and etiology varies by age. About two-thirds of 
strokes occur in those over the age of 65
[23,24]
. It has been observed now that the 
prevalence is becoming high among younger age group and those of low socioeconomic 
status
[25]
 
The AIRs of stroke in India, as observed in the Kolkata, Mumbai, and Trivandrum 
studies are higher than that in United States (107 per100,000 per year), European 
countries (61-111 per 100,000 per year)
[17,18,19]
,and Australia (99 per 100,000 per year)
[21]
 
but similar to that reportedfrom one Chinese city - Changasha.
 [35]
 
 
 Joshi et al.,
[14]
 did a study on mortality because of chronic diseases through verbal 
autopsy in a population of 180,out of which 162 were residing in 45 villages of Andhra 
Pradesh. Death due to stroke(13%) and cardiovascular disease  were similar(14%).
[14]
  
Another community based prospective study done in kolkatta showed a 30-day case 
fatality rate (CFR) 
[15]
 of 41.08% (men, 38.18%; women, 43.24%), which showed a 
significant difference from that seen in the Western countries (17-33%).
[16,17,18,19,21]
 High 
stroke related case fatality rate can be attributed to improper medical care among poor 
people and lesion severity.
[20]
 Another study revealed that genetic factors may also play a 
role as there is greater susceptibility and higher mortality to stroke among UK residents 
16 
of Indian descent.
[22]
 The fatality rates were higher among women, as women outnumber  
men and also have higher prevalence of uncontrolled hypertension than men.
[24]
 In a 
study done in Trivandrum, the 28-day CFRs were 24.5% for urban and 37.1% for rural 
areas.
[23]
 
TABLE 4: Prevalence (PR) of stroke in major Indian studies 
 
 
  
17 
TABLE 5:Data from Trivandrum stroke registry showing urban and rural 
distribution 
 
DEFINITION AND CLASSIFICATION: 
Although more common in older adults, stroke also occurs in neonates, infants, 
children and young adults, resulting in significant morbidity and mortality
[36]
.Stroke is a 
clinical syndrome which is classified broadly into: 
 Ischaemic strokes – These are caused by sudden occlusion of arteries supplying 
the brain, either due to thrombus at the site of occlusion or formed in another part 
of the circulation causing restriction of blood supply to the part of brain causing 
cerebral infarction. It accounts for 50-85% of all strokes worldwide 
[37]
 
 Haemorrhagic strokes – defined as bleed which occurs within substance of the 
brain, intracerebral haemorrhage or contained within the subarachnoid space
[38]
. 
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 Transient ischemic attacks (TIAs) are defined as temporary neurological deficit 
with symptoms lasting less than 24hrs which is thought to be due to inadequate 
cerebral or ocular blood supply as a result of thrombosis or embolism associated 
with arterial, cardiac or haematological disease. It serves as a warning signal for 
impending stroke. It leaves no clinical residue or abnormality on imaging 
[39]
. 
 
Risk factors : 
Risk factors are defined as any attribute, characteristic or exposure of an individual that 
increases the likelihood of developing a disease or injury. Risk factors may be further 
classified as modifiable or non-modifiable. 
 
Non modifiable risk factors: 
Risk factors like age, gender, race/ethinicity and family genetics come under non 
modifiable risk factors. 
1. Gender: Globally, males are affected predominantly regardless of age and stroke 
subtype. In the Indian scenario, this difference observed is due to high prevalence of 
smoking and alcohol among males. The male :female sex ratio among affected 
individuals is 7:1 in India.
[40,41]
 
A few etiologies are confined to the female population. Most of the strokes  
observed commonly among the reproductive age group are due to pregnancy or oral 
contraceptive usage. Though prevalence of occurrence of stroke is high among males, 
prevalence of death is higher among females. 
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2. Race and ethnicity: Blacks are more commonly affected with stroke compared to 
whites. Lack of proper awareness, affordability and no insurance are among the 
contributory factors to this observed difference.
[42,43]
 
3. Family genetics: Family members may have a genetic tendency or share lifestyles 
and behavioural patterns that significantly contribute to the occurrence of stroke. 
Genetic factors for hypertension, Von Willebrand disease, Sickle cell disease may 
also contribute to increased risk of stroke. Risk of stroke further increases with a past 
history of stroke. Although heredity plays only a minor role in the pathogenesis of 
stroke, an increased risk is seen among first-degree relatives with a family history of 
stroke. Heredity factors when combined with an unhealthy lifestyle leads to increased 
risk among individuals. 
[44,45]
 
Modifiable 
 Cigarette smoking – It is one of the most important risk factors of stroke among 
young adults. Risk of stroke increases by four fold among young adults in smokers 
compared to non-smokers. The risk depends on both duration and dosage. Smoking 
more than 20 cigarettes per day carries a higher risk of developing ischemic stroke. 
The risk of stroke increases by enhancing atherogenesis, triggering cardiac 
arrhythmias, arterial thrombosis and vasospasm. It also adds to the economic burden. 
If associated with other risk factors there will be synergistic effect on risk of stroke 
occurrence.
[46]
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 Alcohol consumption – This is another modifiable and preventable risk factor for 
stroke in young adults. It differs among men and women. In men, binge drinking of 
alcohol carries a higher risk of developing ischemic stroke than in non -alcoholics or 
alcoholic abstainers. Binge drinking has the effect of raising blood pressure which 
further increases risk of stroke
[47]
.In men, binge drinking is defined as six or more 
alcoholic drinks whereas it is four or more in women. In women the risk increases 
with increase in intake of alcohol. Consumption of wine has a protective effect.  
 Dyslipidaemia – Atherogenic dyslipidaemia is an independent risk factor of stroke 
among young adults and also plays a role in causing higher prevalence of recurrent 
stroke. Atherogenicdyslipidemia is defined as high levels of low-density lipoprotein 
cholesterol (LDL-C) along with other factors such as high triglycerides (TGL) (TGL 
≥150 mg/dL) and low high-density lipoprotein cholesterol (HDL-C) (HDL-C ≤40 
mg/dL)
[48]
. Elevated apolipoprotein B and A1 levels are also associated with young 
stroke. Elevated LDL and TGL levels increase the intimal thickness of carotid artery 
thereby increasing atherosclerosis.  It is associated with symptomatic intracranial 
stenosis identified by computed tomography (CT) imaging or magnetic resonance 
imaging of cerebral blood vessels (MRI). They comprise a metabolic pattern that may 
be driven by insulin resistance, which ultimately leads to accelerated progression of 
atherosclerotic vascular disease. 
 
21 
 Abdominal obesity – defined as BMI more than 30kg/sq.m. Predisposing mechanism 
of stroke in obese individuals is likely due to its effect on arterial hypertension 
associated with elevated cholesterol levels. It mainly plays an important contributory 
factor for stroke. Upper body obesity is more important than lower body obesity as a 
risk factor
[49]
. Increased waist hip ratio is associated with early death. People should 
be encouraged to increase daily physical activity and reduction of weight in order to 
lessen the risk of stroke.Increased physical activity also decreases platelet aggregation 
and increase insulin sensitivity
[50]
. 
 
 Sedentary life style – It has been a contributory factor for occurrence of stroke in 
young individuals. Blood pressure, impaired glucose tolerance, insulin resistance are 
associated with altered lipid profile with increasing risk for stroke. Lifestsyle 
modifications like regular exercise, weight reduction measures and dietary 
modifications may help decrease incidence. 
 Hypertension – It is defined as systolic blood pressure (SBP) more than 140 mm Hg 
or diastolic blood pressure (DBP) more than 90 mm Hg. It is considered both primary 
as well secondary cause of death among stroke in young adults. 70% of hypertensives 
develop stroke. Hypertension increases wall stress and causes damage of vascular 
endothelium. This damage causes thrombi formation and ischemic lesions mainly 
affecting large extra-cranial vessels. Both elevated diastolic and systolic blood 
pressures are associated with increased concentrations of haemoglobin, which is a risk 
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factor for ischaemic stroke
[51,52]
. Isolated systolic blood pressure and wide pulse 
pressures are at greater risk.  
 
In chronic hypertension, there is vessel wall thickening and luminal narrowing which 
limit the capacity of the resistance vessels for dilation. In acute stroke, auto-regulation 
may be impaired in regions surrounding an acute lesion and even in the hemisphere 
contralateral to the lesion because of dilation of cerebral resistance vessels in an 
attempt to increase blood flow in response to tissue ischemia and acidosis. About 10-
20 mm of Hg decrease in SBP causes reduction of incidence of stroke of 28% in 
young adults
[53]
. 
 
 Diabetes mellitus: Increasing prevalence of diabetes results in an increase of macro-
vascular complications. Thus stroke is one of the long termcomplication of diabetes 
mellitus
[54]
. Three factors fasting blood glucose (FBS), glycosylated haemoglobin 
(HbA1c) and duration of diabetes have significant impact on risk of stroke among 
young adults. FBS more than 241 mg/dl, HbA1c more than 6.5% and duration of 
diabetes for more than 7 years. Stroke occurring in diabetic individuals is usually not 
reversible. Persons with both type 1 and type 2 diabetes mellitus (DM) have increased 
susceptibility affecting both large and small vessels. Diabetes increases fibrinogen 
and clotting factors thereby causing increasing platelet aggregation promoting 
formation of arterial thrombosis
[55]
. There is 11 times higher risk of stroke in young 
adults compared to older age group. Hyperglycemia does not present with signs 
typical of stroke whereas hypoglycaemia can mimic as stroke causing neurological 
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deficits. It is therefore said that prompt treatment of hypoglycaemia in emergency 
conditions in suspicion of stroke. 
 
 Oral contraceptives – risk of stroke in young women taking oral contraceptives is 
four times higher. High dose oestrogen doubles the risk of stroke 
[56]
in women with 
other associated factors like smoking, pro-thrombotic genetic variants and migraine. 
High prevalence of thromboembolic stroke is seen in these conditions
[57]
. Newer oral 
contraceptives with low levels of estrogen are being used to decrease the incidence of 
stroke in women.  
 
 Pregnancy: Pregnancy and puerperium - Estrogen related stroke – Risk of stroke is 
high in third trimester and 6 weeks of post-partum period
[58]
. Preeclampsia and 
eclampsia play a synergistic role leading to nine fold increase in stroke occurrence
[59]
. 
Amniotic fluid embolism, postpartum angiopathy and postpartum cardiomyopathy 
can result in cardio-embolism or infarction due to hypotension. It may also be 
influenced by underlying haemotological or thrombotic conditions 
 
 Illicit drug abuse: Recreational drug abuse in young adults increases the 
susceptibility of stroke in young adults. Injectable drugs are more prone for embolic 
stroke
[60]
. Use of certain drugs (eg, cocaine, amphetamines, crack) having 
sympathomimetic activity causing hypertension, platelet aggregation leading to 
endocarditis causing embolic stroke
[61]
. Attimes, they may cause vasculitis of arteries 
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and arterioles causing stroke. Drugs like heroin, opiates, cannabinoids also play a role 
in etiology of ischemic stroke. 
 Migraine headache – There is increased risk of ischemic stroke among young women 
(35-45years) with migraine headache with aura (MA). The risk is accelerated with 
concomitant use of oral contraceptives, smoking and blood pressure. Cerebral 
ischemia may induce migraine headache
[62,63]
. Most commonly occipital headaches 
are present. It is seen in about one third of total cases. 
ETIOLOGY:  
 Atherosclerotic – thrombotic and cerebral embolic stroke are the predominant cause 
of AIS. 
Atherosclerosis:  
It mainly involves large vessels both intra-cranial and extra-cranial arteries and small 
vessels (lacunar arteries)
[64]
. It begins with damage to the endothelial lining of vessel 
wall. The damaged area attracts platelets, calcium, fatty substances, fibrin and cellular 
debri which accumulate to form an atherosclerotic plaque. These plaque eventually 
increase in size and block the blood flow through the vessel thereby decreasing the 
blood supply leading to hypoxia.  
These plaques become more vulnerable, when the lipid content increases in the 
plaque within the fibrous core. They become easily friable and get detached from the 
vessel form blood clots pass in to the circulation and reach other areas and block the 
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blood vessel
[65]
. The second type of mechanism of stroke called cardio-embolic 
stroke. Cardioembolism is responsible for 20% of all ischemic strokes. Stroke caused 
by heart disease is primarily due toembolism of thrombotic material forming on the 
atrial or ventricular wall or the left heart valves. These thrombi then detach and 
embolizeinto the arterial circulation. The thrombus may fragment or lyse quickly, 
producing only TIA. Alternatively, the arterial occlusion may last longer, producing 
stroke. Embolic strokes tend to occur suddenly with maximum neurologic deficit 
present at onset. Nonrheumatic atrial fibrillation is the most common cause of cerebral 
embolism overall. The presumed stroke mechanism is thrombus formation in the 
fibrillating atrium or atrial appendage, with subsequentembolization. Atrial fibrillation 
causes stasis of blood due to hypocontractile nature of atrium. There occurs atrial 
remodeling, endothelial dysfunction, release of coagulation factors like Xa and 
thrombin. All these factors promote thrombus formation and ultimately lead to 
cerebral embolism.Patients with atrial fibrillation have an average annual risk of 
stroke of -5%
[66]
.Recent MI may be a source ofEmboli, especially when transmural 
and involving the anteroapical ventricular wall, and prophylactic anticoagulation 
following MI has been shown to reduce stroke risk. Mitral valve prolapse is not 
usually a source of emboli unless the prolapse is severe. Paradoxical embolization 
occurs when venous thrombi migrate to the arterial circulation, usually via a patent 
foramen ovale or atrial septal defect. 
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FIGURE 3 : Mechanism of thrombotic process in stroke 
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FIGURE 4 : Atherosclerosis 
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Atheromatous plaques mostly form preferentially at branching points and curves 
of cerebral arteries. The most frequent sites involved are 
 Internal carotid artery at its origin from the common carotid artery 
 In the cervical part of vertebral arteries and at their junction to form basilar arteries 
 In the stem or at the main bifurcation of middle cerebral arteries 
 In the proximal posterior cerebral arteries as they wind around the midbrain 
 In the proximal anterior cerebral arteries as they pass anteriorly and curve around 
corpus callosum. 
 Large artery disease:  
Carotid and vertebral dissections - Defined as tear in intimal layer of vessel leading to 
blood flow in between the layers of vessel wall. The stasis of blood in between the 
vessel layers leads to formation of a clot which can embolise leading to formation of 
stroke
[67]
. It is one of the factors in causing stroke in the young though it becomes a 
rarer cause in older age group. It is commonly caused by trauma to blood vessel. It 
also causes haemorrhagic stroke in young adults. Spontaneous dissection is also seen 
in few individuals, especially in those with connective tissue disorders, increases 
predisposition to stroke. 
 Small artery disease: systemic hypertension and migraine effect the small 
microvasculature causing lacunar infarcts in individuals. 
 Cardioembolism: It is the most common cause of arterial ischemic stroke (AIS) of 
all ages. It occurs very rapidly within seconds. The most common cause is 
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atherosclerosis in older age group. It accounts for about one fifth of ischemic stroke 
[68]
. Most of the cases the emboli arises from a thrombus within heart. The arterial 
ischemic stroke caused by embolism from the heart can only be diagnosed, if there is 
an identifiable cardioembolic source, by using transoesophageal echocardiography. It 
can provide the anatomic location regarding the source of emboli. 
 
Cardiac diseases – they may classified as congenital and acquired. 
o Congenital heart disease is a major risk factor for cardio-embolic stroke especially 
in the perioperative period or following catheterization or extracorporeal 
membrane oxygenation (ECMO).  
o Rheumatic Heart Disease(RHD) – it plays a significant role in causing stroke in 
young adults in developing countries. About 3-8% strokes are attributed to RHD. 
It also plays a role in recurrent stroke. It remains as an occult cause where early 
identification and preventive measures must be taken to reduce the incidence and 
recurrence
[69]
. 
o Acquired conditions –These commonly include Dilated cardiomyopathy (DCM), 
acute myocardial infarction (AMI), infective endocarditis (IE), Atrial Fibrillation 
(AF) and prosthetic valve placement. Coronary artery disease (CAD) share similar 
risk factors as that of stroke. Left ventricular hypertrophy (LVH) and left atrial 
enlargement (LAE) further increases the relative risk of development of stroke
[70]
. 
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 Elevated Homocysteinelevels: Inborn errors of metabolism characterized by 
defect in methionine metabolism due to deficiency of enzyme cystathione b-
synthase(CBS). Common pattern of inheritance is autosomal recessive. Deficiency 
of vitamin B12 and serum folate levels is another factor having a contributory role. 
These enzyme and vitamin deficiencies cause increased accumulation of 
homocysteine levels in plasma and urine. Elevated homocysteine levels causes 
endothelial dysfunction and thromboembolic events affecting both small and large 
vessels causing cerebrovascular ischemia
[71]
. It is mainly diagnosed by measuring 
the levels of homocysteine in urine and plasma. Most of them respond to vitamin 
supplements. 
 
 Fibromuscular dysplasia – This condition mainly affects the medium sized 
vasculature in young women of childbearing age group. It causes medial fibrosis 
of vessel wall due to an unknown mechanism, predominantly involving the carotid 
vasculature
[72]
. Stroke may be thromboembolic or vascular stenosis may be the 
underlying cause. On angiography, a typical beading pattern of involved vessel is 
formed. 
 
 Radiotherapy – Patients who have received radiation for head and neck 
malignancies are more prone to develop delayed onset of arterial 
ischemicstroke
[73]
. Relative risk is doubled with radiotherapy. 
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 Haematological disorders: 
o Thrombophilia: Defined as a group of condition related to the impairment of 
haemostatic mechanism which manifest as an increased tendency to form thrombus. 
They may be classified as inheritable or acquired conditions. Deficiency in natural 
coagulants like protein C, protein S and antithrombin III deficiency, polymorphisms 
in activated protein C and disturbance of clotting mechanisms by mutation in 
prothrombin gene 20210G/A are classified under the inheritable causes. Among the 
inherited conditions, Factor V leiden and prothrombin 20210 mutation are most 
commonly associated with arterial ischemia stroke(AIS)
[74]
. Among acquired 
conditions, Anti-phospholipid antibody syndrome (APLA) is most commonly 
associated with AIS. Acquired conditions are relatively at higher risk of causing 
stroke than inherited conditions. Workup for these conditions with a background of 
prior episode suggestive of thromboembolic event or having a positive family history 
or recurrent pregnancy loss or absence of  other identifiable risk factors
[75]
. Family 
members and siblings should be screened.  
o Myeloproliferative syndromes – They mainly include polycthemiavera (PV), 
myelofibrosis and essential thrombocythemia (ET). They are described to have high 
prothrombotic states which occurs due to inflammatory insult to the vessel wall by 
host immune response towards malignant cells. About 60-70% have arterial 
thrombosis. The risk of thrombosis further increases with the use of myelo-
suppressive drugs
[76]
. If associated with underlying valvular heart disease, there is a 
high risk of cardio-embolic stroke. 
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o Sickle cell anaemia – Stroke in this condition is a near fatal complication. Considered 
mechanism in the etiology of stroke in this condition is that, the deformed sickle cells 
cause vaso-occlussion of vessels leading to stroke. Another mechanism is by 
hemolysis within the vasculature altering the endothelial structure of vessel wall
[77]
. 
This condition mainly affects the large arteries. 
o Vasculitides: Defined as occurrence of inflammation and formation of necrosis of 
vessel wall. It is classified as primary or secondary in nature. Among the primary 
conditions Takayasu’sarteritis,Polyarteritisnodosa (PAN), Wegener’s granulomatosis 
(WG), Behcet’s are common conditions associated with stroke in young individuals. 
Another rare disorder called primary angitis of central nervous system (CNS) a 
multifocal disorder considered one of the cause of stroke in young
[78]
. In these 
conditions, there is inflammation of blood vessel wall which increases the 
thrombogenecity and alter the vessel tone predisposing to stroke. 
o Genetics: It may be single gene disorder or polygenic disorder or metabolic in nature. 
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TABLE 6 
TYPES: GENE MUTATION VESSEL AFFECTED 
CADASIL Notch 3 receptor Small vessel disease 
CARASIL Notch 3 receptor Small vessel disease 
Fabry disease 
(X‐linked recessive) 
α‐galactosidase A Large and small vessel disease 
MELAS (maternal) Transfer RNA Complex 
Marfan syndrome 
(autosomal dominant) 
Fibrillin 1 Cardioembolism and arterial 
dissection 
Ehlers–Danlos 
syndrome (autosomal 
dominant) – type IV 
Collagen type III  
o CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy)- mutation causes progressive degeneration of smooth 
muscle cells in vessel wall causing stroke in late childhood or early adulthood
[79]
. 
High risk for recurrent stroke in young. It is identified by classical MRI changes 
which shows bilateral temporal pole hyperintensity – punctate and nodular lesions. 
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o CARASIL(cerebral autosomal recessive arteriopathy with subcortical infarcts and 
leukoencephalopathy ) – autosomally recessively inherited CADASIL associated 
with acute features of lumbago, spondylosisdeformans, diffuse baldness and 
progressive mental and motor deterioration. Most common age of onset is 25-
30years of age (younger age comparatively to CADASIL). On imaging, it is 
typically identified as diffuse and homogenous lesions.  
 
o MELAS – mitochondrial myopathy, encephalopathy, lacto-acidosis and stroke. It 
is a multisystemicmaternally inherited disorder which are characterised by stroke 
like episodes
[80]
. In this condition mostly posterior regions like temporo-parietal 
and occipital regions are involved. Due to mitochondrial dysfunction, nitric oxide 
metabolism is impaired and free radicals are released which cause impaired auto-
regulation. Cardiomyopathy due to mitochondrial disease may cause cardio-
embolic stroke. They are transient in nature and reflected in abnormalities on 
neuroimaging
[81]
. Muscle biopsy helps in diagnosis, by identifying the abnormal 
proliferation of mitochondria. 
 
o Fabry’s disease – X-linked genetic disorder where there is accumulation of 
lysosomes in vascular endothelium leading to narrowing of the vessels and 
infarction in affected young adult males
[82]
. It involves brain, kidney, heart and 
skin. About 25% of individuals with Fabry’s disease develop stroke involving both 
carotid and vertebrobasilarregions
[83]
. Alpha galactosidase replacement decreased 
the incidence of cerebrovascular incidents. 
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o Heritable disorders of connective tissue – this mainly involves the mutation in 
collagen and elastin content which constitute the vessel wall. Of the disorders 
affecting collagen fibres, Ehlers Danlos syndromes (EDS), osteogenesisimperfecta 
(OI), autosomal dominant polycystic kidney disease (ADPKD) and collagen type 
IV related small vessel disease are most commonly associated with stroke
[84]
. 
These are associated with formation of aneurysms in the vessel wall and are 
complicated with carotid and vertebral artery dissections. Among those affecting 
the elastin content of vessel wall, Marfan’s syndrome, Loeyz Dietz syndrome 
(LDS type I and II) and Pseudoxanthomaelasticum are commonly associated with 
occurrence of stroke in young. 
 
o Amyloid angiopathy: it is associated with amyloid deposition in leptomeningeal 
walls and cerebral arteries and arterioles. Most commonly involves the occipital 
region and considered severe if it involves the same region. Mostly it causes 
haemorrhagic stroke. 
 
o Moyamoyadisease: It is a genetic disorder with AD pattern of inheritance 
characterised by thickening of intimal carotid vessels. It has a bimodal age pattern 
at age of 5 years and 30-50years of age
[85]
. It causes ischemic stroke in younger 
age groups whereas it is associated with haemorrhagic stroke in adults.  
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FIGURE 6: PATHOPHYSIOLOGY OF STROKE 
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ROLE OF ALBUMIN IN ACUTE ISCHEMIC STROKE 
ALBUMIN: 
A) SYNTHESIS: 
Albumin is quantitatively the most important plasma protein. Adult liver 
synthesizes around 15 grams per day. Approximately 300 to 500 grams of 
albumin is distributed in the body fluids. The synthesis rate can double in 
situation in which there is rapid albumin loss or a fall in serum albumin 
concentration. Rate of albumin transcription can be affected due to trauma, 
sepsis, hepatic disease, diabetes , fasting. 
B) STRUCTURE: 
It is a single polypeptide chain of 585 aminoacids with a molecularmass 
of 67 KDa. 
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C) FUNCTION: 
Major functions of albumin include regulation of colloid osmotic pressure of 
plasma,transportation of hormones,fattyacids,drugs and metabolites across 
plasma,regulation of microvascularpermeability,anti-oxidant activity,anti thrombotic and 
anti inflammatory activity. 
 
D) DISTRIBUTION: 
It is a major component of ECF including CSF,interstitial fluid and lymph.Around 40-
60% albumin is degraded in muscle and skin,15% in liver,10% in kidney and 10% in GI 
tract. 
 
E) USES: 
 Because of its unique properties,albumin has been used as therapeutics in the field 
of hepatology. The volume expanding property of albumin is widely used for benefit of 
patients with cirrhosis. Among neurological diseases albumin has a role in ischemic 
stroke,Alzhemier’s  disease and epilepsy. Human albumin in high doses has been used in 
clinical trials for acute ischemic stroke based on its neuroprotective effects. 
 
The Albumin In Acute Stroke (ALIAS) clinical trial was conducted based on the 
fact that albumin in high doses decreases infarct volume and cerebral edema and 
improves behavioural function. 
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FIGURE 7NEUROPROTECTIVE ROLE OF ALBUMIN  
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VOLUME OF INFARCT AND CLINICAL OUTCOME 
The standard measure of therapeutic success in animal stroke models is reduction 
in infarct volume. As a replacement for disability and global clinical scales, reduction in 
infarct volume can be considered an auxiliary outcome measure for human stroke clinical 
trials. Few studies have compared infarct volume and clinical outcome. 
Several small series showed that infarct volume and clinical outcomein terms of BI, 
NIHSS, Rankin Disability Scale had no statistical significance.
[91,92]
Some larger series , 
revealed correlations between infarct volume  and clinical scales (NIHSS, Rankin 
Disability Scale, Oxford Disability Scale, aphasia severity scale).
[93–95]
 
Volume of infarct is calculated using the formula ABC/2. The infarct was measured in 
three perpendicular axes A,B and C 
A = Longest dimension in axis x 
  B = Longest perpendicular dimension to axis x (y) 
  C = Total length in z dimension 
 
Most of the studies in which serum albumin was studied as a predictor of ischemic 
stroke outcome didn’t include volume of infarct . This study compared serum albumin 
and clinical outcome and also volume of infarct and clinical outcome. 
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ANATOMY AND CLINICAL MANIFESTATIONS  
 
o ANATOMY OF CEREBRAL CIRCULATION:  
Brain is the highest perfused organ in the body. It receives about 20% of total 
circulation and also has the maximum consumption of oxygen in the blood. It is 
supplied by two pairs of large arteries – internal carotid arteries and vertebral 
arteries
[78]
. 
Internal carotid artery supplies about 3/5
th
 of cerebrum. The two vertebral 
arteries join together to form basilar artery which supplies cerebellum and brain stem. 
These two arterial circulation join together with the help of communicating branches 
to form circle of willis (COW)
[79] 
 
 
o The internal carotid group produce three main vessel branches which include –   
1. Ophthalmic artery – supplies the meninges, contents of orbit. 
2. Anterior cerebral artery (ACA) – These are a pair of arteries supplying the medial 
portions of frontal lobes along with prefrontal and supplementary motor cortex 
and superior medial parietal lobes. They are further subclassified into 5 smaller 
branches called callosal arteries as they also supply the carpus callosum. Due to 
collateral supply by anterior communicating artery, stroke due to ACA is very 
rare. 
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FIGURE 8: Circle of Willis 
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o Clinical relevance –  
• Occlusion of ACA may cause following symptoms: 
• Contralateral lower limb upper motor neuron type (UMN) of weakness 
• Contralateral sensory loss in lower limb 
• Due to frontal lobe involvement – Behavioural abnormalities, cortical 
release reflexes – grasp reflex, sucking reflex, gegenhalten phenomenon. 
• Transcortical aphasia. 
3. Middle cerebral artery (MCA) – It is also a paired artery which supplies anterior 
temporal and insular cortices. They are connected to ACA with the help of anterior 
communicating branches and connected with PCA with the help of posterior 
communicating branches. They are further divided into 4 parts or segments in their 
course of supply. They supply the bulk of lateral surface of the hemispheres along 
with speech areas (Broca’s and Wernicke’s areas) 
o Clinical relevance –  
• Contralateral upper and lower limb UMN type of paralysis 
• Contralateral sensory loss over face and arm 
• If lenticulostriate branches of MCA are involved –  
 If involvement of dominant hemisphere  aphasia 
 Involvement of non-dominant hemisphere  contralateral neglect 
syndrome  
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4. Posterior cerebral artery (PCA) – it is one of the paired arteries which supply the 
posterior part of the brain which includes occipital lobe. It is divided into 2 
branches – cortical and ganglionic vessels. 
o Clinical relevance –  
• Contralateral loss of pain and temperature 
• Contralateral homonymous hemianopia with macular sparing 
• Alexia and agraphia 
• Weber’s syndrome – third cranial nerve palsy with contralateral hemiplegia 
• Horner’s syndrome  
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FIGURE 9: Blood supply of brain 
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MANAGEMENT: 
NON INVASIVE METHODS: 
 In patients with AIS, diagnosing stroke early plays a key role in many ways: 
 To assess the clinical outcome and prognostication of the condition.  
 To institute thrombolysis whenever possible. 
 It helps further management – mainly in the ED, where it plays a crucial role in order 
to decide about further management. 
Therefore, a standard approach for diagnosis and treatment for stroke must be established 
in primary health care centres and educational institutions for management of stroke in 
emergency.It also helps in assessing the arterial territory involved and area of brain 
affected by examining clinically.Identification and control of modifiable risk factors and 
especially hypertension, is the best strategy to reduce the burden of stroke, and the total 
number of strokes could be reduced substantially by these means. 
 
 
 
 
 
 
 
 
47 
 
FIGURE 10: (A) MRI diffusion-weighted image (DWI) demonstrating a right ventral 
pontine infarction (arrow); (B) MRI-DWI showing a small dorsal left medullary 
infarction (arrow) in a patient presenting with acute isolated vertigo; (C) catheter 
angiogram showing cut-off of the right posterior inferior cerebellar artery (arrow); (D,E) 
MRI-DWI showing massive right cerebellar hemispheric and vermian infarction; (F) 
MRI T2-weighted sequence demonstrating right cerebellar infarction with edema and 
mass effect 
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FIGURE 11 
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FIGURE 12 :MRI (A) MRI fluid-attenuated inversion recovery (FLAIR) sequence 
showing a right lateral medullary infarction with a hypoplastic right vertebral artery.(B) 
catheter angiogram showing stenosis at the vertebrobasilar junction (arrow); (C) non-
contrast CT showing a left posterior cerebral artery territory infarction (D) catheter 
angiogram showing a right distal vertebral dissecting aneurysm with intraluminal 
thrombus (arrow) presenting with vertigo, ataxia, and a right cerebellar infarction. 
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TABLE 7 
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Stroke scoring systems: 
Rapid assessment with the help of scoring systems is needed in the patients with 
suspicion of stroke. Several scoring scales are mainly used to assess the baseline 
characteristics for treatment outcome 
[81]
.In this study, clinical assessment by NIHSS 
scoring scale wasused in Emergency Department to know the severity of stroke at onset 
and used for prognosis and to assess clinical outcome. These scales mainly help in the 
accuracy of diagnosis of AIS and also help in determining the appropriate treatment and 
predicting the outcome. No single scale will be able to assess all the effects of stroke that 
is to say not all parameters of stroke can be assessed completely by these scales. Several 
scoring scales have been designed and standardized. Early imaging of brain either CT or 
MRI with or without angiography has to be done in the ED presented when a patient 
presents with stroke. Thus, haemorrhagic stroke is ruled out wherein the line of 
management differs from that of AIS. 
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Routine baseline investigations to be done are (TABLE 8): 
Complete haemogram  
Blood sugars Hypo or hyperglycemia 
Urine routine Diabetes, infection 
Serum electrolytes Hyponatremia or hypokalaemia or hyperkalaemia 
Renal function tests Renal failure 
Fasting lipids Dyslipidemia 
Homocysteine levels Homocystinemia 
Serology  Vasculitis , Infections, HIV, VDRL 
ECG Left ventricular hypertrophy (LVH), Atrial fibrillation, 
arrhythmias, AMI 
Echocardiography Infective endocarditis, atrial myxoma,mural thrombus 
ESR, CRP Autoimmune causes-vasculitis, SLE 
To do in young stroke  
ANA profile, APLA APLA syndrome, SLE, vasculitis 
Coagulation profile Protein C and S deficiency, anti thrombin III deficiency, 
hyperfibrinogenemia. 
Genetic studies 
(optional)  
CADASIL, MELAS, CARASIL.,etc 
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TREATMENT: 
Treatment is mainly aimed at reversing the hypoxic brain injury and lessen further 
damage of brain from hypoxia caused by decreased blood supply due to occlusion of the 
blood vessels supplying the brain.  
 
At the presentation to ED with acute stroke, the primary management is to assess 
the airway, breathing and circulation initially
[81]
.Treat the hypoglycaemia (<60mg/dl) 
identified on presentation as it may act as a stroke mimic. Hyperglycemia leads to poor 
outcomes in stroke. Hence, early treatment of blood sugars is needed.  
 
Blood pressure:  Reduce the blood pressure by 15% of that of initial presentation within 
24hrs of onset if SBP > 220 mm Hg and DBP >120 mm Hg 
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TABLE 8 
 
 Early fibrinolysis : 
According to AHA/ASA guidelines for the management of AIS, thrombolysis is 
indicated in order to restore the blood flow to the brain and early resolution 
ofneurological deficits. For this purpose, the most commonly used fibrinolytic drug is r-
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tPA(recombinant tissue plasminogen activator). Streptokinase which has a major role in 
AMI, has high incidence of complications in acute AIS. Hence this drug is of not in 
regular use for AIS. It must be decided whether a patient is a feasible candidate for 
fibrinolysis
[81]
.They must be thrombolysed within a window period of maximum of 
4.5hrs from the onset of symptoms. 
 
The FDA approved dose of IV r-tPA is 0.9 mg per kilogram of body weight, 
withamaximum dose of 90 mg. A bolus of 10% of the dose to be given over 1 minute, 
with the remaining 90% to be infused over  60 minutes. Weight should be determined 
reliably. Treatment with a lower dose of r-tPA (0.6 mg per kilogram) in Japan suggest 
that it had similar efficacy but the lower dose has not yet been assessed in large, 
randomized trials. 
Third-generation plasminogen activators, such as Tenecteplase and Desmoteplase, are 
more fibrin specific than second generations r-tPA and cause less activation of systemic 
lytic activity. 
Symptomatic intracranial hemorrhage occurs in 1.7 to 8.0% of treated 
patients.
[87,88]
Recommendations for the treatment of intracranial or major systemic 
bleeding after thrombolytic therapy often includes administration of cryoprecipitate and 
platelets,although evidence-based guidelines for such an approach are lacking
[89,90] 
 10 units of cryoprecipitate (to increase fibrinogen and factor VIII) 
 6-8 units of platelets to be given 
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 In patient receiving UFH consider giving protamine 1mg for every 100 U UFH 
INCLUSION AND EXCLUSION CRITERIA FOR THROMBOLYSIS IN AIS:  
INCLUSION CRITERIA: 
 Onset of symptoms <3 hours before beginning treatment (Onset time is defined as 
either the witnessed onset of symptoms or the time last known normal) 
 Age ≥18 years  
 Potential risks and benefits of IV t-PA treatment discussed with patient and/or 
family members and they have verbalized understanding (to be documented in 
patient’s record). If patient unable to give verbal consent and no family available, 
IV t-PA can be given under Emergency Doctrine. Written informed consent not 
required for IV tPA when given within 3 hours of symptom onset.  
 
EXCLUSION CRITERIA: 
 Significant head trauma or prior stroke in previous 3 months  
 Any history of haemorrhage stroke 
 Intracranial neoplasm, arteriovenous malformation, or aneurysm  
 Recent intracranial or intra-spinal surgery  
 Elevated blood pressure (systolic >185 mm Hg or diastolic >110 mm Hg)  
 Active internal bleeding  
 Blood glucose concentration <50mg/dl (2.7mmol/L)  
 Acute bleeding diathesis, including but not limited to: Platelet count 
<1,00,000/mm³ (In patients without history of thrombocytopenia, treatment with 
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IV rtPA can be initiated before availability of platelet count but should be 
discontinued if platelet count is <100 000/mm³.)  
 Heparin received within 48 hours, resulting in abnormally elevated aPTT greater 
than the upper limit of normal  
 Current use of anticoagulant with INR >1.7 or PT >15 seconds and current use of 
direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive 
laboratory tests (such as aPTT, INR, platelet count, and ECT; TT; or appropriate 
factor Xa activity assays)  
 CT demonstrates multilobar infarction (hypodensity>1/3 cerebral hemisphere)  
 
RELATIVE EXCLUSION CRITERIA: 
 
 Only minor or rapidly improving stroke symptoms (clearing spontaneously)  
 Seizure at onset with postictal residual neurological impairments  
 Major surgery or serious trauma within previous 14 days  
 Recent gastrointestinal or urinary tract haemorrhage (within previous 21 days)  
 Pregnancy  
 
To extend IV tPA to 4.5 hours from symptom onset/last known normal, the following 
additional criteria MUST be met:  
 Patient is < 80 years of age  
 Patient does not have a history of both diabetes AND stroke  
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 Patient is not taking Warfarin (Coumadin) or any other anticoagulant regardless of 
INR/coagulation results  
 NIHSS is < 25  
 Written informed consent obtained from patient and/or family – required when IV 
tPA given within the 3-4.5 hour window.  
 
 Anti coagulants:  
Anticoagulation is not recommended in all patients with AIS in emergency 
condition. Drugs most commonly used are low molecular weight heparin (LMWH) or 
unfractionated heparin (UFH)
[84]
. They can be used to prevent venous thromboembolism. 
Only in the below mentioned specified clinical situations, anticoagulation therapy is 
indicated : 
 Conditions with potential high risk of early cardiogenic reembolization 
 Symptomatic dissection of arteries supplying the brain 
 Symptomatic extra-cranial or intra-cranial atherosclerotic stenosis  
 Basilar artery occlusion before or after intra-arterial pharmacological or 
mechanical thrombolysis 
 Known hypercoagulable states 
 Cerebral venous sinus thrombosis  
 
 
59 
 Anti-thrombotic agents :  
They are mainly used for secondary prevention of stroke. Drugs most commonly used are 
aspirin,clopidogrel and extended release dipyridamole. Newer antiplateletsdabigatran, 
apixaban and rivaroxaban are being studied for anticoagulation comparing with warfarin 
[85].
According to guidelines, aspirin should be given within 24 to 48hrs of onset of stroke 
to prevent mortality and primary end point.  
Endovascular techniques – intra-arterial fibrinolysis, thrombo-embolectomy, suction 
thrombectomy, angioplasty and revascularisation are among the common endovascular 
procedures. The main aim of these is to recanalise the thrombosed vessel to improve the 
blood flow. For this a team of skilled neurologists, interventional radiologists, 
anaesthesiology, nursing and technical support is required for optimal success.  
 Neuro protection:  
Several novel neuro-protective agents like citicholine, traxoprodil, ONO-2506, 
magnesium, DP-b99 and NXY-059 have been identified. They limit the infarct size and 
improve functional outcome (primary end point)
[85]
. They act as free radicals scavengers 
and inhibit further occurrence of neuronal cell death.  
 Rehabilitation centres :  
The main aim of these centres is to improve the quality of life of stroke survivor by 
improving the skills to perform activities of daily living. A team of neurologist, 
psychiatrist, occupational therapist, speech language therapists, dieticians and social 
workers play an important role in achieving the desired result
[86]
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RESULTS 
In this study, about 50 consecutive cases admitted with AIS, which met inclusion and 
exclusion criteria were evaluated. At presentation, along with complete history taking, 
relevant clinical examination, scoring was done based on NIHSS score.mRSscoring 1 
week post admission,3 months later and Volume of infarct in CT scan and clinical 
outcome were analysed in this study. 
 
GENDER 
Among the study population of 50 patients, 44(88%) were males and 6(12%) were 
females. Out of 50 patients,3 patients were lost to followup. 
 
FIGURE 12: Sex Distribution 
 
 
 
SEX DISTRIDUTION
MALE FEMALE
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TABLE 9: Presenting symptoms in study population 
 
SYMPTOMS NO OF PATIENTS % 
HEADACHE  5 10 
VOMITING  4 8 
MOTOR WEAKNESS  18 36 
UNCONSIOUSNESS  6 12 
DYSARTHRIA  11 22 
VERTIGO  3 6 
TINGLING  2 4 
DIPLOPIA  0 0 
CONVULSIONS  1 2 
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TABLE 10: Distribution according to systolic blood pressure ( SBP ) on admission 
SBP MALE FEMALE TOTAL % 
< 138  5 1 6 12 
140 – 158  21 2 23 46 
160 – 178  9 2 11 22 
180 – 198  7 1 8 16  
>200  2 0 2 4 
TOTAL  44 6 50 100 
 
 
TABLE 11:Distribution according to diastolic blood pressure (DBP) on admission  
DBP  MALE FEMALE TOTAL % 
<78  4 0 4 8 
80 – 88  13 2 15 30 
90 – 98  18 3 21 42 
100 – 108  7 1 8 16 
>110  2 0 2 4 
TOTAL  44 6 50 100 
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TABLE 12:Past medical history on study population 
RISK  FACTORS TOTAL MALE FEMALE 
TOBACCO 1 
0 
1 
OLD CVA 5 4 1 
ALCOHOLISM 11 11 0 
IHD 12 12 0 
SMOKING 12 12 0 
DLP 14 13 1 
DM 20 19 1 
SHT 34 30 4 
 
FIGURE 13: 
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TABLE 13: Frequency of lesion in MRI / CT brain 
FREQUENCY OF LESION IN MRI/CT NO OF PATIENTS 
MCA INFARCT 30 
MULTI INFARCT 9 
POSTERIOR CIRCULATION INFARCT 5 
LACUNAR INFARCT 6 
TOTAL 50 
 
FIGURE 14: 
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TABLE 14: Gender and mRS @ 1 week 
Gender 
mRS (1 week) 
Total 
Less than or equal 
to 3 More than 3 
Male 29 14 43 
Female 3 1 4 
Total 32 15 47 
 
FIGURE 15: 
 
 Out of the 43 male patients , 14 patients had significant disability. Among the 14, 
3 had death as outcome. 29 patients had mild disability. Out of the 4 female patients, 1 
had significant disability and died during the first week. Remaining 3 patients had mild 
disability. 
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TABLE 15: Gender and mRS @ 3 months 
Gender 
mRS (3 months) 
Total 
Less than or equal 
to 3 More than 3 
Male 39 4 43 
Female 3 1 4 
Total 42 5 47 
 
FIGURE 16: 
 
Among the male patients, no of patients with significant disability dropped from 
14 to 4.In the female group,the 3 patients with mild disability had improvement in the 
mRS score and didn’t worsen. 
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TABLE 16 :Gender and serum albumin level 
 
Gender 
Serum Albumin Level 
Total 3-3.4 3.5-3.9 4-4.4 >4.4 
Male 1 11 24 8 44 
Female 0 2 3 1 6 
Total 1 13 27 9 50 
 
FIGURE 17: 
 
 
Among 50 patients , only one patient had low serum albumin levels. Majority of patients 
had albumin levels between 4 to 4.4.Both male and female groups were similar. 
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TABLE 17: Gender and NIHSS score 
 
Gender 
NIHSS Score 
Total 
Less than or equal 
to 10 More than 10 
Male 37 7 44 
Female 4 2 6 
Total 41 9 50 
 
FIGURE 18: 
 
On admission, no. of males who had NIHSS more than 10 were 7. No of females who 
had NIHSS more than 10 were 2. 
 
 
0 20 40 60
Male
Female
G
en
d
er
37
4
7
2
NIHSS Score Less than or 
equal to 10
NIHSS Score More than 10
69 
TABLE 18: Age and mRS @ 1 week 
Age 
mRS (1 week) 
Total Less than or equal to 3 More than 3 
26-35 1 1 2 
36-45 2 2 4 
46-55 9 5 14 
56-65 9 6 15 
>65 11 1 12 
Total 32 15 47 
 
FIGURE 19: 
 
Among the 47 patients , no of people who had significant disability were 15.Among them 
6 were in the age group of 56 to 65. No of people who had mild disability were 
32.Among them about 11 people were in the age group more than 65. 
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TABLE 19: Age and mRS @ 3 months 
Age 
mRS (3 months) 
Total Less than or equal to 3 More than 3 
26-35 2 0 2 
36-45 3 1 4 
46-55 12 2 14 
56-65 13 2 15 
>65 12 0 12 
Total 42 5 47 
 
FIGURE 20: 
 
 
After 3 months , number of people with significant disability were 5 and number of 
people with mild disability were 42.Significant improvementwas seen in the age group of 
56 to 65 ( 9 to 13 ). 
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TABLE 20: Age and Serum Albumin Level 
Age 
Serum Albumin Level 
Total 3-3.4 3.5-3.9 4-4.4 >4.4 
26-35 0 0 1 1 2 
36-45 0 0 3 2 5 
46-55 1 4 6 3 14 
56-65 0 5 9 2 16 
>65 0 4 8 1 13 
Total 1 13 27 9 50 
 
FIGURE 21: 
 
Mean albumin is 3.8.Only one patient in the age group of 46 to 55 had low serum 
albumin .Each group had high no of patients in the albumin range 4 to 4.4. 
  
0
2
4
6
8
10
12
14
16
26-35 36-45 46-55 56-65 >65
Age
0 0 1 0 0
4 5 4
1
3
6
9
8
1
2
3
2
1
Serum Albumin Level 
>4.4
Serum Albumin Level 4-
4.4
Serum Albumin Level 
3.5-3.9
Serum Albumin Level 3-
3.4
72 
TABLE 21: Age and NIHSS score 
 
Age 
NIHSS Score 
Total Less than or equal to 10 More than 10 
26-35 2 0 2 
36-45 5 0 5 
46-55 9 5 14 
56-65 13 3 16 
>65 12 1 13 
Total 41 9 50 
 
FIGURE 22: 
 
No. of people with NIHSS score less than or equal to 10 was 41 and more than 10 was 9. 
NIHSS score of 10 or less than 10 was seen in high numbers in 56-65 and >65 years age 
group. 
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TABLE 22:Serum Albumin with mRS after 1 week 
 
Serum Albumin Level 
mRS (1 week) 
Total P value 
Less than or 
equalto 3 More than 3 
<3.5 g/dl 0 1 1  
 
0.319 
> or = 3.5 g/dl 32 14 46 
Total 32 15 47 
 
FIGURE 23: 
 
Serum albumin level was compared with mRSscore. No of people with serum albumin 
>3.5 and mRS less than or equal to 3 are 32 and with mRS> 3 are 14. No of people with 
serum albumin<3.5 and mRS>3 are 1. Pvalue was 0.319. Hence there was no significant 
correlation. 
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TABLE 23: Serum Albumin with mRS after 3 months 
Serum Albumin Level mRS (3 months) 
Total P value Less than or equal 
to 3 More than 3 
<3.5 g/dl 1 0 1  
0.894 > or = 3.5 g/dl 41 5 46 
Total 42 5 47 
 
FIGURE 24: 
 
 
Serum albumin level and mRS score after 3 months were compared. Number of  patients 
with serum albumin >3.5 and mRS< 3 increased from 32 to 41. The patient with serum 
albumin <3.5 had an improvement in mRS score. Eventhough there was improvement in 
patients clinically, statistically there was no significant correlation as the p value was 
0.894. 
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TABLE 24: Volume of Infarct in CT Scan withmRS after 1 week 
 
 
FIGURE 25: 
 
 
N Mean 
Std. 
Deviation Std. Error 
95% Confidence Interval for 
Mean 
Minimum Maximum P value Lower Bound Upper Bound 
Less than or equal to 3 32 5.5948 12.00600 2.12238 1.2662 9.9234 .11 52.54  
 
.001 
More than 3 14 26.5182 26.47135 7.07477 11.2341 41.8023 .30 81.60 
Total 46 11.9628 19.91184 2.93584 6.0497 17.8759 .11 81.60 
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FIGURE 26:Scatter Plot of infarct volume VsmRS @ 1 week 
 
 
Out of 47 patients , volume of infarct could not be calculated for one patient . For 
remaining patients volume of infarct and mRS scale was compared using ANOVA 
method. P value was 0.001.This shows that there was significant correlation between the 
volume of infarct and outcome during first week. 
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TABLE 25: Volume of Infarct in CT Scan with MRS after 3 months 
 
N Mean 
Std. 
Deviation Std. Error 
95% Confidence Interval for 
Mean 
Minimum Maximum 
 
 
 
P value 
Lower 
Bound Upper Bound 
Less than or equal to 3 42 10.6385 17.63608 2.72131 5.1428 16.1343 .11 62.70  
 
0.146 
More than 3 4 25.8675 37.60486 18.80243 -33.9702 85.7052 1.57 81.60 
Total 46 11.9628 19.91184 2.93584 6.0497 17.8759 .11 81.60 
 
FIGURE 27: 
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FIGURE 28:Scatter Plot of infarct volume VsmRS @ 3 months 
 
The volume of infarct and mRS scale was compared during 3
rd
 month using ANOVA 
method. P value was 0.146 . This showed there was no correlation between volume of 
infarct and outcome during third month. 
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TABLE 26 :Serum Albumin with NIHSS Score 
Serum Albumin 
Level 
NIHSS Score 
Total P value Less than or 
equal to 10 More than 10 
3-3.4 0 1 1  
 
 
0.124 
3.5-3.9 10 3 13 
4-4.4 24 3 27 
>4.4 7 2 9 
Total 41 9 50 
 
FIGURE 29: 
 
Most of the previous studies showed that patients with good outcome had lower NIHSS 
score and high serum albumin level on admission and those with worst outcome showed 
high NIHSS score and low serum albumin level. In this study also patient with good 
outcome had low NIHSS and high albumin. Only one patient had low albumin and high 
NIHSS score. P value was 0.124.Hence there is no significant correlation between serum 
albumin and NIHSS score in this study, contrary to other studies. 
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DISCUSSION 
The mean age group of the study population was 53 years, predominantly middle 
aged group which is a decade lower than the peak group of stroke in western countries.
[96]
 
 
In this study, male patients had more severe stroke compared to female patients. 
Diabetes mellitus and systemic hypertension were the most common risk factors 
observed in the study. Around 42 patients had good outcome in this study and only 5 
patients had poor outcome. The patients with poor outcomes had a mean volume of 
infarct of around 26.51 and those with good outcome had a mean volume of infarct of 
around 5.59. Eventhoughthere was significant correlation between volume of infarct and 
mRS score at 1 week there was no significant correlation between them at 3 months. 
Earlier studies showed that increasing age was associated with increased hospital stay and 
poor outcome. This study was contrary to the above reports. All the patients above 65 
years at 3 months had mRS score<3. 
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STUDY NO OF PATIENTS MEAN ALBUMIN P VALUE 
Reeta et al
[100]
 100 3.73 Significant 
Idicula et al
[98]
 444 3.76 <0.05 
Dziedzic et al
[97]
 759 3.55 <0.01 
Gaurav et al
[99]
 50 3.81 <0.001 
   Present study 50 3.85 0.894 
 
 In 2004 Dziedzic et al conducted a study in Poland. Around 759 patients with 
ischemic stroke were taken up for study. Using modified Rankin Scale outcome was 
measured 3 months post stroke. Serum albumin levels were compared with functional 
outcome at third month. This study reported that those patients with poor outcome had a 
lower serum albumin levels compared to those with non poor outcome. The study by 
Idicula et al observed that Ischemic stroke patients with high serum albumin had better 
outcome and low mortality. This study also showed that there is significant association 
between serum albumin and age. Hardly few studies have been done in India comparing 
serum albumin levels and functional outcome. To the best of our knowledge we could 
find only two studies regarding the same in India. Both studies compared serum albumin 
levels with short term functional outcome in ischemic stroke patients.  Reeta et al 
conducted a study in Kerala. 100 patients were included in the study. This study 
concluded that serum albumin has an influence in stroke severity and outcome. The other 
Indian study was conducted by Gaurav et al in Jodhpur. 50 patients were included in the 
study. This also found a significant association between serum albumin levels and short 
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term functional outcome. These two studies didn’t compare serum albumin levels with 
functional outcome at third month. Most western studies and Indian studies didn’t take 
volume of infarct into account which also plays a significant role in the outcome. A study 
by Mallemoggala et al has found that patients with low albumin levels had high incidence 
of recurrence. 
 In this study, most patients with a good outcome had lower NIHSS score,low mRS 
score,high albumin and low volume of infarct. Those with worst outcome had higher 
NIHSS, high mRS,high volume of infarct and high albumin. The one patient with low 
serum albumin also had a good outcome in 3 months. As opposed to study by Idicula et al 
this study didn’t show any association between serum albumin and age. Thus not only 
serum albumin but volume of infarct also plays a role in the final outcome of the patient - 
this was not considered in other studies .Those who had poor outcome had a mean 
volume of infarct of around 25 cc and also there was stastistical significance between 
volume of infarct and mRS at 1 week. Eventhough clinically most of the patients had 
good outcome after 3 months based on mRSscore, statistically p value was not 
significant. Hence this study is contrary to the evidence that serum albumin is a long term 
predictor of ischemic stroke outcome. The disadvantage of this study was that of sample 
size which was low compared to other western studies and the number of people with low 
albumin levels were low. 
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Albumin has a wide range of intravascular effects. It reduces hematocrit level and 
also plays a vital role in aggregation of erythrocytes  by increasing low shear viscosity 
and decreasingerythrocyte sedimentation under no-flow conditions. Albumin has a good 
antioxidant property. Other neuroprotective effect of albumin in stroke includes  
A) Prevention of thrombosis and 
B) Prevention of leukocyte adhesion within postcapillary microcirculation in the 
early reperfusion phase. 
 
Albumin captures the oxygen free radicals and slows the production of reactive 
hydroxyl radical species. Albumin has a peculiar property of binding to copper ions by 
doing so it inhibits the process of copper ion dependent lipid peroxidation at cell 
membrane. It has also been postulated that albumin exerts neuroprotection by binding to 
lysophosphatidylcholine. Free lysophosphatidylcholine increases leukocyte adhesion 
molecules which leads to inflammatory mediated damage on vascular endothelium. It 
also causes apoptosis when it is present in high concentration. Based on the above  
properties it was postulated that albumin infusion post ischemic stroke may be beneficial 
in long term outcome. 
 
Research studies in rats done by Belayev et al. showed that functional outcome, 
volume of infarct and brain edema had a significant improvement after high-dose human 
albumin therapy, when administered within 2 to 4 hours after onset of stroke. Based on 
all the evidences human trial known as ALIAS (AlbuminIn Acute Ischemic Stroke) was 
conducted. Dosage of albumin (Intravenous 25%) used in this trial was 2g/kg. There was 
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no significant outcome after 90 days. High incidence of intracerebral haemorrhage and 
pulmonary edema were noted
[100]
. Further research is required to come to a definite 
conclusion that human albumin infusion can improve the clinical outcome of stroke 
patients. 
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CONCLUSION 
 
Stroke being a major health concern in developing countries it is high time we get 
a suitable predictor for its outcome.Diabetes and systemic hypertension were the most 
common risk factors associated.This study indicates that higher levels of serum albumin 
isNOT a predictor of ischemic stroke outcome .It is contrary to the literature already 
present. Further larger studies are required to come to ascertain the facts and its 
implications for therapy. 
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 PROFORMA 
 Name  
 Age 
 Sex 
 Address  
 Occupation  
 Chief  complaints 
 H/o  cocaine  abuse  or  any  other  substance  abuse  or  use  of  oral  contraceptives 
 H/o  smoking,  alcohol,  diabetes,  hypertension,  seizure  disorder,  bleeding  
disorders,  migraine, thrombosis,  rheumatic  heart  disease,  ischaemic  heart  disease,  
severe  LV  dysfunction, arrhythmias (mainly  atrial  fibrillation) 
 H/o  head  trauma  
 Family  history  of  thrombosis,  hyperlipidaemia,  hypertension, diabetes 
 
 
 
 
 
 
 
 
 CLINICAL EXAMINATION 
 General examination 
 CNS examination: 
o Speech – dysarthria or aphasia (motor / sensory/ global) 
o Cranial nerves 
o Weakness of limb  
o Power – UL and LL 
o Sensory  
o Cerebellar  
o Carotid and subclavian bruits, murmurs 
o Peripheral pulses 
o NIHSS on admission 
o mRS after 1 week and after 3 months 
 
 Routine investigations: 
o Complete blood count, Diabetic profile 
o Serum albumin, electrolytes, urine routine and microscopy 
o ECG, ECHO, serum homocysteine levels 
CT- brain plain, MRI brain with angiography 
 
 
 
 ABBREVIATIONS 
AIS – Arterial ischemic stroke 
WHO - World  Health  Organization  
TOAST - Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. 
ANA – Anti nuclear antibody profile 
APLA – Anti-phospholipid antibody 
CT – Computed tomography 
MRI – Magnetic resonance imaging  
NIHSS - National  Institute  of  Health  stroke  scale 
mRS – modified rankin scoring 
TIA - Transient ischemic attacks  
LDL-C - low-density lipoprotein cholesterol  
TGL - Triglycerides  
HDL-C - High-density lipoprotein cholesterol (HDL-C) 
BMI – Body mass index 
SBP – Systolic blood pressure 
DBP – Diastolic blood pressure 
 FBS - fasting blood glucose 
HbA1c - glycosylated haemoglobin  
DM – Diabetes mellitus 
MA – Migraine headache with aura  
RHD - Rheumatic heart disease 
DCM - Dilated cardiomyopathy  
AMI – Acute myocardial infarction 
IE – Infective endocarditis 
AF – Atrial Fibrillation  
CAD – Coronary artery disease  
LVH – Left ventricular hypertrophy 
LAE – Left atrial enlargement  
PV – Polycthemiavera 
ET - Essential thrombocythemia 
PAN – Polyarteritisnodosa 
WG – Wegener’s granulomatosis 
CNS - Central nervous system  
 CADASIL – Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy 
CARASIL – Cerebral autosomal recessive arteriopathy with subcortical infarcts and 
leukoencephalopathy 
MELAs – Mitochondrial myopathy, encephalopathy, lacto-acidosis and stroke 
EDS – Ehlers Danlos syndromes  
OI – Osteogenenis imperfect  
ADPKD - Autosomal dominant polycystic kidney disease (ADPKD) 
LDS - Loeyz Dietz syndrome  
AD – Autosomal dominant 
COW – Circle of willis 
ACA – Anterior cerebral artery 
MCA – Middle cerebral artery 
PCA – Posterior cerebral artery 
UMN – Upper motor neuron type  
ED – emergency department 
HIV – human immunodeficiency virus 
ECG – Electrocardiogram 
 ECHO – Echocardiography 
AHA/ASA – American heart association / American stroke association 
r-tPA – Recombinant tissue plasminogen activator 
NINDS – National institute of Neurological Disorders and Stroke 
aPTT – Activated partial thromboplastin time  
INR – International normalised ratio 
PT – Prothrombin time 
UFH – Unfractionated heparin 
LMWH – Low molecular weight heparin 
 
 
 
 
 
 
 
 
  
 PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
I Dr. JOEL FRANKLIN F am carrying out a study on the topic:SERUM ALBUMIN 
LEVEL AS A PREDICTOR OF ISCHEMIC STROKE OUTCOME as part of our 
research project being carried out under the aegis of the Department of General Medicine. 
 
My research guide is: Dr. SUJAYA MENON 
 
The justification for this study is: Cerebrovascular diseases include some of the most 
common and devastating disorders:Ischemic stroke and haemorrhagic stroke.Stroke is the 
second leading cause of death worldwide.So if there is a suitable predictor for ischemic 
stroke outcome it will enable us to monitor the patients closely and also can be applied it 
for therapeutic intervention as in the case of albumin. 
 
Location: PSG Hospitals 
 
We request you to kindly cooperate with us in this study. We propose collect background 
information and other relevant details related to this study. We will be carrying out: 
Clinical examination on admission and serum albumin levels will be taken within 36 
hours.mRS scale will be done one week and 3 months later. 
 
 Data collected will be stored for a period of three years. We will not use the data as part 
of another study. 
 
INITIAL INTERVIEW: Approximately 15 minutes 
 
Clinical examination will be done to asses other clinical findings 
 
Risks involved by participating in this study: Blood prick for collecting sample 
 
How the results will be used: The results of the study will be submitted to THE 
TAMILNADU DR MGR MEDICAL UNIVERSITY as a part of thesis programme in 
post graduate course of general medicine 
 
If you are uncomfortable in answering any of our questions during the course of the 
interview / biological sample collection, you have the right to withdraw from the 
interview / study at anytime. You have the freedom to withdraw from the study at any 
point of time. Kindly be assured that your refusal to participate or withdrawal at any 
stage, if you so decide, will not result in any form of compromise or discrimination in the 
services offered nor would it attract any penalty. You will continue to have access to the 
regular services offered to a patient. You will NOT be paid any remuneration for the time 
you spend with us for this interview / study. The information provided by you will be 
kept in strict confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall be used for 
approved research purposes only. You will be informed about any significant new 
 findings - including adverse events, if any, – whether directly related to you or to other 
participants of this study, developed during the course of this research which may relate 
to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to me, 
and has been explained to me by the investigator/s. Having understood the same, I hereby 
give my consent to them to interview me. I am affixing my signature / left thumb 
impression to indicate my consent and willingness to participate in this study (i.e., 
willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
 
Signature of the Interviewer with date:      Witness: 
 
Contact number of PI: 9894927206 
 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 
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S.No SEX AGE CHIEF COMPLAINTS COMORBID CONDITIONS DIAGNOSIS VOLUME OF INFARCT IN CT SCAN NIHSS SCORESERUM ALBUMIN LEVEL MRS AFT 1 WEEKMRS AFTER 3 MONTHS MRS AFT 3 MONTHS
1 M 56
DIFFICULTY IN USING OF RT UL & LL, SLUURING 
OF SPEECH RHD, MVR, AF+CVR, MOD.LVD RT HEMIPLEGIA+ MOTOR APHASIA
39 13 3.9 4 3 3
2 M 62
GIDDINESS,SWAYING WHILE 
WALKING,SLURING OF SPEECH. NO COMBID CONDITION POSTERIOR  CIRCULATION STROKE
7.4 3 4.3 4 2 2
3 M 40
WEAKNESS IN LEFT UPPER AND LOWER LIMBS T2DM,SHTN,ALCOHLIC,DLP. LEFT HEMIPLEGIA
25.17 8 4.6 4 2 3
4 M 80
DIFFICULITY IN USING RIGHT UPPER AND 
LOWER LIMBS T2DM,SHTN,CAD,MILD LVD. CVA WITH RIGHT HEMIPARESIS
2.3 6 4 3 2 1
5 M 58 DIFFICULITY IN USING RIGHT UPPER LIMBS HTN,,ALCOHOLIC,DLP  CVA WITH RIGHT MONOPARESIS. 7.5 5 4.4 1 3 1
6 M 53
WEAKNESS IN RIGHTUPPER AND LOWER LIMBS DM,SHT CVA WITH RIGHT HEMIPLEGIA
50.18 12 3.9 4 2 3
7 M 49
DIFFICULITY IN USING RIGHT UPPER AND 
LOWER LIMBS,DIFFICULITY IN SPPEC DM,DLP. CVA WITH RIGHT HEMIPLEGIA.
45.36 13 3.1 4 3 3
8 M 65
DIFFICULITY IN USING LEFT UPPER AND LOWER 
LIMBS. HTN,IHD CVA WITH LEFT HEMIPLEGIA
29 10 4.3 1 0 0
9 F 47
DIFFICULITY IN USING RIGHT UPPER AND 
LOWER LIMBS.SLURRING OF SPEECH HTN HTN CVA WITH RIGHT HEMIPLEGIA.
1.72 8 4.3 3 1 1
10 M 32
DIFFCULITY IN USING LEFT UPPER AND LOWER 
LIMBS,FASCIAL PALSY SMOKER,ALCHOLIC CVA WITH LEFT HEMIPLEGIA
0.88 10 4.1 4 3 3
11 M 27
DIFFICULITY IN USING RIGHT UPPER AND 
LOWER LIMBS SMOKER,ALCHOLIC YOUNG STROKE
8.76 9 4.6 3 3 3
12 M 42
DIFFICULITY IN USING RIGHT UPPER AND 
LOWER LIMBS SHT,CVD CVA WITH RIGHT HEMIPARESIS
0.3 7 4.1 3 2 2
13 M 44
DIFFICULITY IN USING RIGHT UPPER AND 
LOWER LIMB NO COMBID CONDITION CVA WITH RIGHT HEMIPARESIS
1.42 10 4.6 3 2 1
14 M 72
WEAKNESS IN RIGHT UPPER AND LOWR LIMBS. SHT,ALCOHOLIC,SMOKER CVA WITH LEFT HEMIPARESIS
1.98 7 4.6 3 0 2
15 M 45
WEAKNESS IN LEFT UPPER AND LOWER 
LIMBS,SLURRING OF OLD CVA,,SHT,DLP,SMOKING,SPEECH,FASCIAL PALSY.ACSRECURRENT CVA
1.57 10 4.4 5 3 5
16 M 58 WEAKNESS IN RIGHT UPPER AND LOWER 
LIMBS,SLURRINGOF SPEECH,FACIAL PALSY. HT,IHD,
52.54 8 4.1 3 2 2
17 M 48
 MILD FASCIAL PARESIS,SWAYING IN ONE LIMB, HT,IHD,DM,EX SMOKER& ALCOHOLIC  
1.26 3 3.5 0 0
18 M 54 DROWSINESS, DECLARED 5.06 30 3.8  DECLARED
19 M 75
WEAKNESS IN RIGHT UPPER AND LOWER LIMB SHT,DM,DLP POSTERIOR CIRCULATION STROKE.
0.2 7 4.3 1 0
20 M 55 WEAKNESS IN LEFT UPPER LIMB DM,SHT, CVA WITH LEFT HEMIPARESIS 2.03 1 4.3 1 0
21 M 55
WEAKNESS IN LEFT UPPER AND LOWER LIMB NO COMBID CONDITION ACUTE INFRACT IN RT FRONTAL BONE
1.08 10 4.2 3 2
22 M 62
SWAYING WHILE WALKING,SLUURING OF 
SPEECH. SHT,DLP.SMOKER ACUTE INFRACT INRT CEREBELLAR REGION
30.89 3 4.1 1 1
23 M 65
WEAKNESS IN LEFT UPPER AND LOWER LIMB NO COMBID CONDITION ACUTE INFRACT IN RT MCA TERRITORY.
0.52 2 4.1 1 1
24 M 60 SWAYING WHILE WALKING SHT,TOBACCO CHEWER ACUTE INFRACT LEFT MEDULLARY INFARCT 0.24 4 4.2 1 1
25 M 50 WEAKNES RIGHT IN UPPER LIMB SHT/DM RIGHT UPPER LIMB MONOPARESIS. 0.45 4 3.6 1 1
26 F 64 ATAXIA, TOBACCO CHEWER LEFT CEREBELLAR INFARCT 4 3.8 LOST FOLLOW UP LOST TO FOLLOW UP
27 F 70 WEAKNESS IN B/L LIMBS NO COMBID CONDITION ACUTE INFRACT  LEFT INTERNAL CAPSULE AND THALAMUS. 0.11 13 4.4 1 0
28 M 51
WEAKNESS IN  RIGHT UPPER AND LOWR 
LIMB,FACIAL PALSY TYPE 2 DM CVA WITH RIGHT HEMIPLEGIA
0.66 11 4 0 0
29 F 70 FACIAL PALSY,LIMBATAXIA,DYSARTHRIA SYSTOLIC HT, CEREBELLAR STROKE 0.67 3 4 1 0
30 M 66
FACIAL PALSY,WEAKNESS IN RIGHT UPPER AND 
LOWER LIMB NO COMBID CONDITION CVA WITH RIGHT HEMIPARESIS
0.58 5 4.1 3 1
31 M 60 FACIAL PALSY,LIMBATAXIA HTN,SMOKER,ALCOHLIC INFRACT IN RIGHT OCCIPITAL AND RIGHT CENTRUM SEMIOVALE0.9 2 5 0 0
32 M 50 FACIAL PALSY,LIMB ATAXIA,DYSARTHRIA SHT, LEFT ATAXIC HEMIPARESIS 0.271 3 4.3 1 1
33 M 60
FACIAL PALSY ,WEAKNESS IN LT UL AND LL 
,DYSARTHRIA SHT,T2DM,SMOKER RT CAPSULOGANGLIONIC INFRACT
0.52 6 3.6 3 2
34 M 50
SLURRING OF SPEECH,GIDDINESS AND 
UNRESPONSIVENESS HT ON IRRX BRAIN DEAD
NOT ABLE TO ASSESS 30 4.5 BRAIN DEAD
35 M 70 FACIAL PALSY AND DYSARTHRIA T2DM,SHT,DLP,TIA CVA RT THALAMIC INFRACT 0.163 2 4.2 1 0
MASTER CHART
S.No SEX AGE CHIEF COMPLAINTS COMORBID CONDITIONS DIAGNOSIS VOLUME OF INFARCT IN CT SCAN NIHSS SCORESERUM ALBUMIN LEVEL MRS AFT 1 WEEKMRS AFTER 3 MONTHS MRS AFT 3 MONTHS
36 M 49
FACIAL PALSY ,WEAKNESS IN RT UL AND LL, SHT,IHT,POST CABG,DLP SEVERE RT HEMIPARESIS
0.9 6 4.7 3 2
37 M 73 POSTERIOR CIRCULATION STROKE SHT,DM,DLP POSTERIOR CIRCULATION STROKE 0.11 0 4.1 0 0
38 M 50
FACIAL PALSY,DECREASED SENSATION AND 
DYSARTHRIA DM,SHT.ALCOHOLIC,SMOKER,IHT RT WALLENBURGH SYN,BILATERAL CEREBELLAR INFRACT
62.7 3 4.5 4 3
39 M 56 LIMB ATAXIA SHT,T2DM,ALCOHOLIC CEREBELLAR STROKE 36.31 2 4 4 3
40 F 65
FACIAL PALSY,DROWSINESS,WEAKNESS IN RT 
UL AND LL NONE CVA WITH RT HEMIPLEGIA
81.6 17 4.7 DECLARED DECLARED
41 M 75 ATAXIA,DYSARTHRIA T2DM ISCHEMIC STOKE IN LT PONTINE 0.2 2 3.8 1 0
42 M 55 DIFFICULITY IN USING BOTH UL &LL. HT,DM CVA 1.05 10 3.9 3 2
43 M 71 WEAKNESSIN LEFT UPPER LIMB SHT,DLP,CAD,TVD,T2DM CVA WITH RT PARIETAL INFARCT 3.17 2 3.8 1 0
44 M 68
WEAKNESS IN THE LT UL AND LL ,DYSARTHRIA DLP,OLD CVA RECURRENT CVA ,PARIETAL INFRACT
0.485 9 4 5 3
45 M 55
 DIFFICULITY IN USING LEFT UPPER  LIMB AND 
LOWER LIMB SMOKER,ALCHOLIC,SHT,CAD,DYSLIPIDEMIA ACUTE CVA -LEFT MEDULLARY INFRACT.
0.24 4 4.2 1 1 0
46 M 60
WEAKNESS IN THE LT UP AMD LL AND 
DYSARTHRIA DLP,SMOKER,ALCOHOLIC RT MCA INFRACT
15.24 9 4.1 4 4
47 M 72 FACIAL PALSY &DYSARTHRIA HTN,DM CVA 27.3 2 4.3 1 1
48 M 44
WEAKNESS IN LEFT UPPER AND LOWER LIMBS NO COMBID CONDITION CVA WITH RIGHT HEMIPLEGIA
9 4.3 LOST FOLLOW UP LOST TO FOLLOW UP LOST TO FOLLOW UP
49 F 74
DIFFICULITY IN BOTH UPPER AND LOWER 
LIMBS.FASCIAL PALSYTYPE 2DM HTN, 
BA,HYPOTHYROID CVA 
10 3.6 OST FOLLOW UP LOST FOLLOW UP. LOST TO FOLLOW UP
50 M 60
WEAKNESS IN THE RT UL,DYSARTHRIA,FACIAL 
PALSY SHT,IHT,DM,PTCA CVA RT HEMIPLEGIA
0.3 14 4.4 4 3
